TermGallery
Английский
Английский
Испанский
Каталонский
Португальский
Русский
RU
English
Español
Català
Português
Русский
русский
бортезомиб
португальский
bortezomibe
испанский
bortezomib
Chemical compound.
peptide boronate
ps-341
velcade®
medication
chemical compound
русский
бортезомиб
1
These biomarkers data begin to illuminate
bortezomib
's
mechanism of action in lymphoma.
2
Results: Thirty-one per cent of patients received
bortezomib
beyond first relapse.
3
However, apoptotic response to
bortezomib
was not affected by the deletion of p53.
4
Recently, it has been shown that
bortezomib
treatment enhances OB function.
5
The safety profile was consistent with that reported for single-agent
bortezomib
and romidepsin.
6
These data suggest that
bortezomib
-
induced
plasma cell depletion triggers humoral compensation.
7
We tested the signature in independent cohorts treated with
bortezomib
-
and lenalidomide-based therapies.
8
After repeated treatment, initially sensitive lung tumors became resistant to
bortezomib
.
9
The synergistic interaction between oHSV and
bortezomib
was calculated using a Chou-Talalay analysis.
10
The combination of
bortezomib
and IFN-a can be safely administered to melanoma patients.
11
The proteasome inhibitor
bortezomib
is an efficacious apoptotic agent in many tumor cells.
12
The degree of proteasome inhibition was similar to that reported with single-agent
bortezomib
.
13
When possible, all subsequent doses of
bortezomib
within each cycle were provided at home.
14
Conversely, none of the patients who received a treatment without
bortezomib
developed muscular symptoms.
15
Conclusion: Both
bortezomib
plus rituximab regimens seem feasible in relapsed or refractory indolent lymphomas.
16
This delineates another therapeutic mechanism of
bortezomib
in T-cell malignancies.
bortezomib
treat with bortezomib
receive bortezomib
add bortezomib
benefit from bortezomib
compare bortezomib
русский
бортезомиб
португальский
bortezomibe
velcade
испанский
bortezomib